Quadrivalent Influenza Vaccine

BIOLOGICAL20 trials

Sponsors

Green Cross Corporation, Jiangsu Province Centers for Disease Control and Prevention, Vanderbilt-Ingram Cancer Center, PT Bio Farma, Women's and Children's Hospital, Australia

Conditions

COVID-19Cost-EffectivenessHematopoietic Cell Transplantation RecipientImmune ResponseInfluenzaInfluenza (Healthy Volunteers)Influenza Immunization (Healthy Volunteers)Influenza Vaccine

Phase 1

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

CompletedNCT02121782

Green Cross CorporationInfluenza

Start: 2014-05-31End: 2014-06-30Updated: 2014-08-13

Phase 2

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

CompletedNCT02860039

Vanderbilt-Ingram Cancer CenterHematopoietic Cell Transplantation Recipient, Influenza, Malignant Neoplasm

Start: 2016-09-30End: 2024-09-30Updated: 2024-10-22

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

CompletedNCT03336593

PT Bio FarmaSafety Issues

Start: 2017-11-21End: 2018-11-30Updated: 2019-04-02

Phase 3

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

CompletedNCT02710409

Jiangsu Province Centers for Disease Control and PreventionInfluenza

Start: 2016-01-31End: 2016-08-31Updated: 2016-09-01

A Clinical Trial of A Quadrivalent Influenza Vaccine

CompletedNCT03744104

Shanghai Institute Of Biological ProductsInfluenza

Start: 2018-10-11End: 2019-10-08Updated: 2024-01-02

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam

CompletedNCT03765437

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2019-01-15End: 2019-03-17Updated: 2022-04-25

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

CompletedNCT03853993

Sinovac Biotech Co., LtdSeasonal Influenza

Start: 2018-01-23End: 2018-10-08Updated: 2019-02-27

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

CompletedNCT03859141

Sinovac Biotech Co., LtdSeasonal Influenza

Start: 2018-02-06End: 2018-11-02Updated: 2019-03-01

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

CompletedNCT04210349

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2020-01-09End: 2020-12-01Updated: 2025-09-16

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

CompletedNCT05540522

PfizerInfluenza, Human

Start: 2022-09-12End: 2024-03-12Updated: 2025-05-08

Phase 4

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

CompletedNCT04667117

Novartis PharmaceuticalsRelapsing Multiple Sclerosis

Start: 2021-01-14End: 2023-07-06Updated: 2024-10-09

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Jiangsu Province Centers for Disease Control and PreventionInfluenza

Start: 2021-09-19End: 2022-04-30Target: 240Updated: 2022-03-31

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

CompletedNCT05313893

Jiangsu Province Centers for Disease Control and PreventionInfluenza

Start: 2021-09-11End: 2022-05-30Updated: 2022-08-17

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

CompletedNCT05970887

Catholic Kwandong UniversityImmune Response, Safety

Start: 2022-10-12End: 2023-12-15Updated: 2024-03-26

Cost-effectiveness of the Influenza Vaccination

International Centre for Diarrhoeal Disease Research, BangladeshCost-Effectiveness, Influenza Vaccine, Vaccination

Start: 2022-09-29End: 2024-09-30Target: 2567Updated: 2023-08-18

Unknown Phase

Optimising Protection for Pregnant Women and Infants With Maternal Vaccination

Active, not recruitingNCT03457194

Women's and Children's Hospital, AustraliaObesity

Start: 2018-08-28End: 2024-03-01Updated: 2024-01-31

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

CompletedNCT05078060

Sanofi Pasteur, a Sanofi CompanyInfluenza (Healthy Volunteers)

Start: 2021-10-12End: 2021-12-02Updated: 2023-03-24

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

CompletedNCT05568979

Sanofi Pasteur, a Sanofi CompanyInfluenza (Healthy Volunteers)

Start: 2022-10-06End: 2022-11-29Updated: 2024-03-13

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

CompletedNCT05858450

PfizerCOVID-19, Influenza, Human

Start: 2023-05-05End: 2023-05-12Updated: 2024-09-20

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

CompletedNCT06059456

SanofiInfluenza Immunization (Healthy Volunteers)

Start: 2023-10-02End: 2023-12-15Updated: 2025-03-24

Related Papers

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.

2025-11-01

Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study.

2025-03-082 citations

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories

Human Vaccines & Immunotherapeutics2025-02-242 citations

Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season

The Journal of Infectious Diseases2024-09-164 citations

Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh

BMC Public Health2024-01-203 citations

The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial

Clinical Infectious Diseases2023-10-0615 citations

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults

PLoS ONE2023-08-242 citations

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Human Vaccines & Immunotherapeutics2022-11-037 citations

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.

2020-07-2711 citations

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China

Human Vaccines & Immunotherapeutics2020-04-2917 citations

Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study

Vaccine2019-12-174 citations